Bhutan vs Nepal: Average cost of drugs for extensively drug-resistant tuberculosis
Bhutan
2,259 constant 2022 US$
in 2024
Nepal
2,853 constant 2022 US$
in 2024
Bhutan rank
23rd
Nepal rank
21st
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Bhutan
- Nepal
How they compare
Nepal currently reports 2,853 constant 2022 US$ against 2,259 constant 2022 US$ in Bhutan, a difference of 594 constant 2022 US$.
That makes Nepal's figure about 1.3 times Bhutan's.
The two have swapped places 3 times across 6 shared years of data; in 2019 it was Bhutan ahead.
Bhutan ranks 23rd and Nepal ranks 21st of 56 countries.
Across the 2 decades both report, Bhutan averaged higher in 1 and Nepal in 1.
Head to head by decade
| Decade | Bhutan | Nepal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,951 constant 2022 US$ | 2,240 constant 2022 US$ | 711 constant 2022 US$ | Bhutan |
| 2020s | 2,259 constant 2022 US$ | 2,995 constant 2022 US$ | 735.6 constant 2022 US$ | Nepal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Bhutan or Nepal?
- Nepal, at 2,853 constant 2022 US$ against 2,259 constant 2022 US$ in Bhutan as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Bhutan and Nepal?
- 594 constant 2022 US$, with Nepal ahead.
- How many years of comparable data are there for Bhutan and Nepal?
- 6 years are reported by both, from 2019 to 2024.
- How do Bhutan and Nepal rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Bhutan ranks 23rd and Nepal ranks 21st of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.